99 related articles for article (PubMed ID: 1805453)
1. Glucocorticoid-induced osteoporosis: a cross-sectional study.
Brandli DW; Golde G; Greenwald M; Silverman SL
Steroids; 1991 Oct; 56(10):518-23. PubMed ID: 1805453
[TBL] [Abstract][Full Text] [Related]
2. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
Kaji H; Yamauchi M; Chihara K; Sugimoto T
Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced osteoporosis: is the bone density decrease the only explanation?
Lespessailles E; Poupon S; Adriambelosoa N; Pothuaud L; Siroux V; Bouillon S; Benhamou CL
Joint Bone Spine; 2000; 67(2):119-26. PubMed ID: 10769104
[TBL] [Abstract][Full Text] [Related]
4. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
5. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid-induced osteoporosis in patients with sarcoidosis.
Adler RA; Funkhouser HL; Petkov VI; Berger MM
Am J Med Sci; 2003 Jan; 325(1):1-6. PubMed ID: 12544077
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
8. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
Sosa M; Jódar E; Saavedra P; Navarro MC; Gómez de Tejada MJ; Martín A; Peña P; Gómez J
Eur J Intern Med; 2008 Jan; 19(1):51-6. PubMed ID: 18206602
[TBL] [Abstract][Full Text] [Related]
10. Childhood-onset disease carries a higher risk of low bone mineral density in an adult population of systemic lupus erythematosus.
Mok CC; Wong SN; Ma KM
Rheumatology (Oxford); 2012 Mar; 51(3):468-75. PubMed ID: 22096013
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density changes in women with systemic lupus erythematosus.
Boyanov M; Robeva R; Popivanov P
Clin Rheumatol; 2003 Oct; 22(4-5):318-23. PubMed ID: 14579164
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
Koetz KR; Ventz M; Diederich S; Quinkler M
J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
[TBL] [Abstract][Full Text] [Related]
13. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.
Pichette V; Bonnardeaux A; Prudhomme L; Gagné M; Cardinal J; Ouimet D
Am J Kidney Dis; 1996 Jul; 28(1):105-14. PubMed ID: 8712204
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
15. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
16. Bone status in glucocorticoid-treated men and women.
Leib ES; Winzenrieth R
Osteoporos Int; 2016 Jan; 27(1):39-48. PubMed ID: 26252975
[TBL] [Abstract][Full Text] [Related]
17. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in rural Thai adults living in Khon Kaen province.
Pongchaiyakul C; Rojroongwasinkul N; Chotmongkol R; Kosulwat V; Charoenkiatkul S; Rajatanavin R
J Med Assoc Thai; 2002 Feb; 85(2):235-44. PubMed ID: 12081125
[TBL] [Abstract][Full Text] [Related]
19. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study.
Boomsma MM; Stegeman CA; Kramer AB; Karsijns M; Piers DA; Tervaert JW
Osteoporos Int; 2002 Jan; 13(1):74-82. PubMed ID: 11883409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
